Trials / Completed
CompletedNCT05553366
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,075 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SUZ | Tablets for oral administration. |
| DRUG | HB/APAP | Capsules for oral administration. |
| DRUG | Placebo (matched to SUZ) | Placebo matched to SUZ for oral administration. |
| DRUG | Placebo (matched to HB/APAP) | Placebo matched to HB/APAP for oral administration. |
Timeline
- Start date
- 2022-10-03
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2022-09-23
- Last updated
- 2025-08-01
- Results posted
- 2025-08-01
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05553366. Inclusion in this directory is not an endorsement.